Literature DB >> 11189712

Hendra virus disease in horses.

H A Westbury1.   

Abstract

The author provides an account of the discovery of a previously undescribed disease of horses and a description of the studies involved in determining the aetiology of the disease. The causative virus, now named Hendra virus (HeV), is the reference virus for a proposed new genus within the virus family Paramyxoviridae. The virus is a lethal zoonotic agent able to cause natural disease in humans and horses and experimentally induced disease in cats, guinea-pigs and mice. The virus also naturally infects species of the family Megachiroptera, mainly subclinically, and such animals are the natural host of HeV. The virus appears to transmit readily between species of Megachiroptera, but not readily between horses under natural and experimental conditions, or from horses to humans. The method of transmission from bats to horses is not known. Three incidents of HeV disease in horses have been recorded in Australia--two in 1994 which caused the death of two humans and fifteen horses and one in 1999 which involved the death of a single horse. Hendra virus is related to Nipah virus, the virus that caused disease and mortality in humans, pigs, dogs and cats in Malaysia during 1998 and 1999.

Entities:  

Mesh:

Year:  2000        PMID: 11189712     DOI: 10.20506/rst.19.1.1203

Source DB:  PubMed          Journal:  Rev Sci Tech        ISSN: 0253-1933            Impact factor:   1.181


  11 in total

1.  Nipah virus: vaccination and passive protection studies in a hamster model.

Authors:  V Guillaume; H Contamin; P Loth; M-C Georges-Courbot; A Lefeuvre; P Marianneau; K B Chua; S K Lam; R Buckland; V Deubel; T F Wild
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.

Authors:  Gabriel N Defang; Dimple Khetawat; Christopher C Broder; Gerald V Quinnan
Journal:  Vaccine       Date:  2010-11-02       Impact factor: 3.641

Review 3.  Ephrin-B2 and ephrin-B3 as functional henipavirus receptors.

Authors:  Kai Xu; Christopher C Broder; Dimitar B Nikolov
Journal:  Semin Cell Dev Biol       Date:  2011-12-30       Impact factor: 7.727

Review 4.  Viral Hyperparasitism in Bat Ectoparasites: Implications for Pathogen Maintenance and Transmission.

Authors:  Alexander Tendu; Alice Catherine Hughes; Nicolas Berthet; Gary Wong
Journal:  Microorganisms       Date:  2022-06-16

5.  Development of a neutralization assay for Nipah virus using pseudotype particles.

Authors:  Azaibi Tamin; Brian H Harcourt; Michael K Lo; James A Roth; Mike C Wolf; Benhur Lee; Hana Weingartl; Jean-Christophe Audonnet; William J Bellini; Paul A Rota
Journal:  J Virol Methods       Date:  2009-03-09       Impact factor: 2.014

Review 6.  Henipavirus infections: lessons from animal models.

Authors:  Kévin P Dhondt; Branka Horvat
Journal:  Pathogens       Date:  2013-04-09

Review 7.  Assessment of the viral safety of antivenoms fractionated from equine plasma.

Authors:  Thierry Burnouf; Elwyn Griffiths; Ana Padilla; Salwa Seddik; Marco Antonio Stephano; José-María Gutiérrez
Journal:  Biologicals       Date:  2004-09       Impact factor: 1.856

8.  Targeted strategies for henipavirus therapeutics.

Authors:  Katharine N Bossart; John Bingham; Deborah Middleton
Journal:  Open Virol J       Date:  2007-09-28

9.  Rescue and characterization of recombinant cedar virus, a non-pathogenic Henipavirus species.

Authors:  Eric D Laing; Moushimi Amaya; Chanakha K Navaratnarajah; Yan-Ru Feng; Roberto Cattaneo; Lin-Fa Wang; Christopher C Broder
Journal:  Virol J       Date:  2018-03-27       Impact factor: 4.099

10.  A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats.

Authors:  Jennifer A McEachern; John Bingham; Gary Crameri; Diane J Green; Tim J Hancock; Deborah Middleton; Yan-Ru Feng; Christopher C Broder; Lin-Fa Wang; Katharine N Bossart
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.